Hemostemix Inc
OTC: HMTXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas A. Smeenk
- Employees
- 488
- Headquarters
- Calgary, Canada
- IPO year
- 2016
- Market cap
- $7.4M
- Website
- http://www.hemostemix.com
Loading HMTXF…
Loading profile data…Frequently asked questions about HMTXF
What does Hemostemix Inc (HMTXF) do?
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen a...
Where does HMTXF trade?
Hemostemix Inc (HMTXF) trades on the Other OTC.
What sector is HMTXF in?
Hemostemix Inc (HMTXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hemostemix Inc?
Thomas A. Smeenk is the chief executive officer of Hemostemix Inc (HMTXF).
Where is Hemostemix Inc headquartered?
Hemostemix Inc is headquartered in Canada.
Does HMTXF pay a dividend?
Hemostemix Inc (HMTXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HMTXF go public?
Hemostemix Inc (HMTXF) completed its initial public offering in 2016.